Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma
about
Loss of the EP2 prostaglandin E2 receptor in immortalized human keratinocytes results in increased invasiveness and decreased paxillin expressionEndothelin receptors as novel targets in tumor therapyRelationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significanceCyclooxygenase in the treatment of glioma: its complex role in signal transductionSelective induction of cyclooxygenase-2 plays a role in lysophosphatidic acid regulated Fas ligand cell surface presentationClinical implication of expression of cyclooxygenase-2 and peroxisome proliferator activated-receptor gamma in epithelial ovarian tumoursOvarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progressionA seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohortsHigh and low frequency subharmonic imaging of angiogenesis in a murine breast cancer modelActivity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factorsCyclooxygenase-2 inhibitors in gynecologic practice.An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas.Anti-endothelin drugs in solid tumors.Cyclin D1 expression and the inhibitory effect of celecoxib on ovarian tumor growth in vivo.Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma riskCombined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian carcinoma in vivo.Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment.Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment.Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancerExpression of peroxisome proliferator activated receptor gamma and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma.Systematic review of adjuvant care for women with Stage I ovarian carcinoma.Effects of cyclooxygenase inhibitors in combination with taxol on expression of cyclin D1 and Ki-67 in a xenograft model of ovarian carcinoma.Effects of cyclooxygenase inhibitors on survival time in ovarian cancer xenograft-bearing miceSustained adrenergic signaling leads to increased metastasis in ovarian cancer via increased PGE2 synthesis.Age dependent increase in prostaglandin pathway coincides with onset of ovarian cancer in laying hens.Cyclooxygenase-2: a novel target in human solid tumors.mRNA stability control: a clandestine force in normal and malignant hematopoiesis.Cyclo-oxygenase-2 and its inhibition in cancer: is there a role?Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis.Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancerSelective cyclooxygenase inhibitors increase paclitaxel sensitivity in taxane-resistant ovarian cancer by suppressing P-glycoprotein expressionUse of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts.Inflammation and cancer: how friendly is the relationship for cancer patients?Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies.Anti-inflammatory effects of fish oil in ovaries of laying hens target prostaglandin pathways.The importance of endothelin axis in initiation, progression, and therapy of ovarian cancer.Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies.CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer.
P2860
Q24684962-CED2C806-D82D-463F-87F8-76194E63FB8DQ24797288-03A7ECEE-C4D9-4A99-9A0B-12B805E442A1Q24813854-3CB45041-D828-48C4-BC71-FC44361EB135Q28168685-E3DC3A60-87DC-402A-8147-A1BA17570FC8Q28194138-94567A6F-4627-4083-B284-DF13B69AC96AQ28209267-8C462BB9-CA66-4A0B-84EA-671C4B2608FEQ28210448-59FF43AB-DF1A-4A90-987E-1D3C351A262DQ28728722-2A3985A1-75C8-4E31-8D17-DF23D9BEFC10Q30375548-E38642AC-3F3C-4030-A9AF-C63644C866D0Q33365433-6B87317A-2284-470F-A14C-0E5DB411B30DQ33488520-796A2A80-FA99-42EE-A197-F6374506076EQ33723348-2885C2CB-5DD6-4D1F-860D-3025F7C6F548Q33960748-A811E7BB-AF26-49FB-8E69-9F504B1E9553Q34021011-C48CFD4F-9924-46D3-84D2-C49620371C5BQ34378095-4119D507-AB4D-4ACB-B306-5A0501F1B03DQ34453715-C47CF8EC-FC1C-4C66-B28C-DC297B9B4AABQ34578154-E8C6AE8E-B1E9-4D0B-85E1-2B7351EF11F8Q35043366-78B9EC4E-ADB9-4A11-8959-5E908607B0A3Q35098085-F913D9C9-95FE-4B69-83A9-7B46DC0B794BQ35631181-47576A5F-13F0-4DA2-8B37-80E2829CFA68Q35770556-E51F4E42-70A2-4C6D-ABBA-5467E1351205Q35903639-C2535CC3-1129-4CFD-A41F-E3FF2731E01EQ36202284-3778703A-73B6-4717-A8B9-3DF0D6B1E8EFQ36424290-525CC345-FA5E-4F7D-87BF-500427C294D1Q36568221-54AD29CC-E425-46B1-910C-E8D40B263FC5Q36670219-F7A0ADA8-07A7-479A-9FA1-6C7067A704E5Q36731517-C16A7D36-172F-47BA-9088-A7C4E0645FCCQ36773503-4342A884-1C15-44AE-AA0C-8564EDBAFE02Q36788347-866BC4BE-8E0D-4CD0-8D69-04EDB0CCCDBDQ36857782-9BE1C6C9-2402-432B-8F86-D3869E5A7240Q36975194-7013910A-FF30-4702-B1E5-C7A598DD557AQ37022528-BCCE7FE5-7F41-451C-B55F-26671237B62EQ37306176-CF4238DA-90EE-4494-B0B7-18FCFEF09B42Q37316105-B7E0F558-4450-48F7-9C05-9C2652F0715EQ37328373-6AC63B9A-3974-459E-A476-E8612D1C3F0CQ37418407-4E8C2C88-32FE-4BB7-8722-E73CEE8FAD03Q37764250-568B1126-44BB-4A1C-B515-67B5C8959537Q37842973-436C4ED0-8B5C-459C-944B-777F2928D6CBQ38449651-E80C7A01-14C4-48F4-A680-DAC2485AB723Q38753870-A6DA11E6-0F23-4C03-8132-6A4C7E70F171
P2860
Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Expression of cyclooxygenase 2 ...... tor in human ovarian carcinoma
@ast
Expression of cyclooxygenase 2 ...... tor in human ovarian carcinoma
@en
type
label
Expression of cyclooxygenase 2 ...... tor in human ovarian carcinoma
@ast
Expression of cyclooxygenase 2 ...... tor in human ovarian carcinoma
@en
prefLabel
Expression of cyclooxygenase 2 ...... tor in human ovarian carcinoma
@ast
Expression of cyclooxygenase 2 ...... tor in human ovarian carcinoma
@en
P2093
P2860
P1476
Expression of cyclooxygenase 2 ...... tor in human ovarian carcinoma
@en
P2093
Angela Reles
Antje Siegert
Bernd Klosterhalfen
Michael Schwabe
Stefan Berger
Steffen Hauptmann
Sören Pest
P2860
P304
P356
10.1016/S0002-9440(10)64912-7
P407
P577
2002-03-01T00:00:00Z